<DOC>
	<DOCNO>NCT00122343</DOCNO>
	<brief_summary>This open-label nonrandomized multi-center study design evaluate effect AP23573 patient recurrent persistent endometrial cancer . The primary objective ass efficacy AP23573 patient recurrent persistent endometrial cancer administer daily 5 consecutive day ( QDx5 ) every two week dose 12.5 mg/day .</brief_summary>
	<brief_title>AP23573 Female Adult Patients With Recurrent Persistent Endometrial Cancer ( 8669-019 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>≥18 year age histologically confirm endometrial cancer Documented progression endometrial cancer ( e.g. , within last 3 month ) If childbearing potential , must agree use approve barrier method contraception ( non hormonal method ) Presence least one measurable lesion accurately measure least one dimension long diameter ≥20 mm use conventional technique ≥10 mm spiral compute tomography ( CT ) scan ( otherwise least twice reconstruction interval CT magnetic resonance image [ MRI ] scan ) . Previously irradiated lesion may consider measurable provide : *there document progression lesion ( ) since completion radiotherapy ; *the criterion measurability outline meet . ECOG performance status ≤ 2 Minimum life expectancy 3 month Adequate renal hepatic function , define : Total serum bilirubin ≤ 1.5 x ULN institution ; AST and/or ALT ≤ 2 x ULN institution ; Alkaline phosphatase &lt; 1.5 x ULN institution ( &gt; 1.5 x ULN , alkaline phosphatase liver fraction must &lt; 1.5 ULN ) ; Serum albumin ≥ 2.5 g/dL ; Serum creatinine ≤ 1.5 x ULN institution . Adequate bone marrow function , define : ANC ≥ 1.5 x 10^9/L ; Platelet count ≥ 100 x 10^9/L . Serum cholesterol &lt; 350 mg/dL triglyceride &lt; 400 mg/dL Able understand give write informed consent Women pregnant lactate Presence brain metastasis More 2 prior regimen cytotoxic chemotherapy enzyme inhibitor therapy Prior therapy rapamycin , rapamycin analogue tacrolimus ; know sensitivity agent Anticancer treatment ( chemotherapy , radiotherapy , immunotherapy , biological response modifier , signal transduction inhibitor , etc . ) within 4 week prior first dose AP23573 . The interval may ≥ 2 week hormonal therapy signal transduction inhibitor halflife know &lt; 24 hour must ≥ 6 week nitrosourea mitomycin . Ongoing toxicity associate prior anticancer therapy ( except peripheral neuropathy ≤ Grade 1 National Cancer Institute [ NCI ] toxicity criterion ) Another primary malignancy within past three year ( except nonmelanoma skin cancer cervical carcinoma situ ) Known suspect hypersensitivity drug formulate polysorbate 80 ( Tween ) excipient contain study drug Known Grade 3 4 hypersensitivity macrolide antibiotic ( e.g. , clarithromycin , erythromycin , azithromycin ) Significant uncontrolled cardiovascular disease Active infection require systemic therapy Known HIV infection Treatment investigational agent within 4 week prior first dose AP23573 Concurrent treatment immunosuppressive agent prescribed corticosteroid stable dos ≥ 2 week prior first plan dose study drug . Nasal , ophthalmic , topical glucocorticoid preparation allow well low dose maintenance steroid therapy condition . Physiologic hormone replacement therapy ( e.g. , thyroid supplementation thyroid deficiency oral replacement glucocorticoid therapy adrenal insufficiency ) allow . Inadequate recovery prior surgical procedure undergone major surgical procedure within 2 week prior first dose AP23573 . Patients recover placement central venous access port within 2 week Cycle 1 , Day 1 consider eligible . Presence lifethreatening illness organ system dysfunction , opinion Investigator , would either compromise patient 's safety interfere evaluate safety study drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Endometrial</keyword>
	<keyword>Cancer</keyword>
</DOC>